BioSpace News Archive

Tekni-Plex Healthcare has acquired precision extrusion manufacturer Johnson Plastic Group (JPG) as part of a strategy to expand the company’s patient care solutions platform.

The field of medical research has a new tool to develop vaccines, personal immunotherapies, and cures for cancer and other infectious diseases using Full Spectrum Profiling™ (FSP™) technology.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), today announced a wholly owned subsidiary of the Company has entered into a definitive membership interests purchase agreement with Martin Von Dyck, the sole member and owner of North Carolina-based CapNostics, LLC, which manufactures EsophaCap®—a U.S. FDA 510(k)-cleared and European CE Mark certified.

Psygen is excited to announce that psilocybin recently used in a clinical trial was manufactured by Psygen personnel working with a third-party licensed dealer.

Today, the U.S. Food and Drug Administration announced several actions related to surgical stapler and staple regulation and safety.

The Axia Institute of Michigan State University announced the creation of Axia Lab™, a premier research and consulting service leading the way in radio frequency identification (RFID) tagged item assessments, testing, compliance, and technical implementations.

LimFlow SA, the pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), on Wednesday announced 24-month results from the PROMISE I Study of the LimFlow Percutaneous Deep Vein Arterialization System (“LimFlow System”),

DArcy Compliance Consulting is a consulting firm specializing in building compliance cultures within early-stage Life Science companies to assure adherence to regulatory requirements and industry standards.

Apotex Corp. has donated a total of 25,000 fluvoxamine tablets and placebo tablets to the Duke Clinical Research Institute for the ACTIV-6 clinical study funded by the National Institutes of Health (NIH) to evaluate repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19 for non-hospitalized patients.

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced NKX019 and NKX101 clinical development program updates.